CHK2 (I157T)
Sign in to save this workspaceCHEK2 · Variant type: point · HGVS: p.I157T
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Alectinib | 97.3% | 2.8% | 95.49 |
| 2 | Sunitinib | 95.0% | 5.0% | 91.73 |
| 3 | Brigatinib | 94.2% | 5.8% | 82.96 |
| 4 | Ponatinib | 92.6% | 7.4% | 78.23 |
| 5 | Selpercatinib | 86.7% | 13.3% | 96.72 |
| 6 | Ceritinib | 86.1% | 13.9% | 95.44 |
| 7 | Bosutinib | 82.7% | 17.3% | 87.22 |
| 8 | Neratinib | 74.3% | 25.6% | 93.18 |
| 9 | Gilteritinib | 68.2% | 31.8% | 88.97 |
| 10 | Vandetanib | 52.5% | 47.5% | 95.74 |
| 11 | Fedratinib | 51.8% | 48.2% | 96.21 |
| 12 | Dacomitinib | 40.4% | 59.6% | 97.99 |
| 13 | Cabozantinib | 31.6% | 68.4% | 92.73 |
| 14 | Lenvatinib | 31.2% | 68.8% | 97.74 |
| 15 | Afatinib | 28.4% | 71.6% | 98.50 |
| 16 | Capivasertib | 27.2% | 72.8% | 96.48 |
| 17 | Tivozanib | 26.2% | 73.8% | 92.42 |
| 18 | Gefitinib | 23.4% | 76.6% | 99.25 |
| 19 | Crizotinib | 19.5% | 80.5% | 91.39 |
| 20 | Defactinib | 19.3% | 80.7% | 92.68 |
| 21 | Baricitinib | 17.7% | 82.3% | 97.99 |
| 22 | Lorlatinib | 17.4% | 82.6% | 97.24 |
| 23 | Nintedanib | 14.8% | 85.2% | 90.23 |
| 24 | Lazertinib | 12.9% | 87.1% | 97.47 |
| 25 | Canertinib | 11.1% | 88.9% | 96.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Alectinib | 97.3% | 98.8% | -1.6% |
| Sunitinib | 95.0% | 95.0% | +0.0% |
| Brigatinib | 94.2% | 99.4% | -5.3% |
| Ponatinib | 92.6% | 92.6% | +0.0% |
| Selpercatinib | 86.7% | 86.3% | +0.4% |
| Ceritinib | 86.1% | 88.8% | -2.7% |
| Bosutinib | 82.7% | 91.4% | -8.7% |
| Neratinib | 74.3% | 76.1% | -1.8% |
| Gilteritinib | 68.2% | 82.5% | -14.3% |
| Vandetanib | 52.5% | 58.3% | -5.8% |
| Fedratinib | 51.8% | 50.0% | +1.7% |
| Dacomitinib | 40.4% | — | — |
| Cabozantinib | 31.6% | 43.3% | -11.7% |
| Lenvatinib | 31.2% | — | — |
| Afatinib | 28.4% | 31.6% | -3.3% |
| Capivasertib | 27.2% | 30.4% | -3.2% |
| Tivozanib | 26.2% | 32.8% | -6.6% |
| Gefitinib | 23.4% | 30.7% | -7.3% |
| Crizotinib | 19.5% | — | — |
| Defactinib | 19.3% | 38.9% | -19.6% |
| Baricitinib | 17.7% | — | — |
| Lorlatinib | 17.4% | 34.3% | -16.9% |
| Nintedanib | 14.8% | — | — |
| Lazertinib | 12.9% | 35.3% | -22.3% |
| Canertinib | 11.1% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.8ms